A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
NCT ID: NCT05603039
Last Updated: 2022-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
80 participants
INTERVENTIONAL
2021-07-01
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT05976568
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
NCT06822985
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
NCT07138885
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
NCT05411757
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
NCT07327788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cohort A was the dose exploration phase of the study, with 2 dose groups designed, QL1706 5mg/kg q3w + bevacizumab 7.5mg/kg q3w group and QL1706 5mg/kg q3w + bevacizumab 15mg/kg q3w group, to explore the safe dose of bevacizumab.
After approximately 20 cases are enrolled in the bevacizumab safety dose group identified in Cohort A, enrollment will be initiated in Cohort B. Cohort B will be QL1604 200 mg fixed dose q3w + bevacizumab safety dose, and random enrollment will be used for both Cohort A and Cohort B.
The decision to initiate a cohort C study will be based on the preliminary results of the efficacy analysis of cohort A and cohort B. If a Cohort C study is initiated, the Cohort C dosing regimen will be QL1706 7.5 mg/kg q3w + bevacizumab safe dose q3w.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QL1706(5mg/kg)
QL1706(5mg/kg) Combined with Bevacizumab
QL1706
5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Bevacizumab
15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
QL1604
QL1604 Combined with Bevacizumab
QL1604
200mg#D1#Q3W IV
Bevacizumab
15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
QL1706(7.5mg/kg)
QL1706(7.5mg/kg) Combined with Bevacizumab
QL1706
5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Bevacizumab
15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QL1706
5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
QL1604
200mg#D1#Q3W IV
Bevacizumab
15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years old at the time of signing the informed consent form, male or female.
3. Advanced hepatocellular carcinoma diagnosed by histopathology or clinical diagnosis, with disease unsuitable for radical surgery and/or local treatment, or disease progression after surgery and/or local treatment.
4. No prior systemic treatment for HCC.
5. Child-Pugh liver function classification of grade A versus better grade B.
6. Eastern Cooperative Oncology Group (ECOG) physical status score of 0-1.
7. Expected survival ≥ 3 months.
(9) Functional level of vital organs must be compliant prior to first administration of trial drug.
(10) Subject agrees to use effective contraception for contraception from the time of signing the informed consent until 180 days after the last use of the trial drug. Females of childbearing age cannot be in pregnancy or breastfeeding.
Exclusion Criteria
2. Patients with a history of other malignancies within 5 years prior to signing informed consent.
3. Active autoimmune disease that may have worsened during the course of receiving study drug therapy.
4. Concomitant disease that interferes with the subject's ability to complete the study.
5. History of allogeneic hematopoietic stem cell transplantation or organ transplantation.
6. HIV-positive patients; HCV antibody-positive and HCV RNA-positive patients; patients with co-infection with HBV and HCV.
7. Patients with a known history of psychotropic substance abuse, alcoholism, or drug use
8. Those who have participated in other clinical studies and have used other clinical trial drugs within 4 weeks prior to the use of the trial drug
9. Prior immunotherapy or prior targeted therapy.
10. PCP treatment requires 2 weeks of elution before enrollment and is prohibited during the trial.
11. Known previous hypersensitivity to macromolecular protein agents, or any component of the test drug.
12. Live vaccination within 4 weeks prior to the first administration of the test drug.
13. History of hemoptysis, or history of gastrointestinal bleeding, intestinal obstruction and/or previous clinical signs or symptoms of gastrointestinal obstruction.
14. Abdominal or bronchoesophageal fistula, gastrointestinal perforation or intra-abdominal abscess, major vascular disease.
15. Current or recent treatment with aspirin, clopidogrel, or current or recent treatment with dipyridamole, ticlopidine, and cilostazol; use of anticoagulation therapy for therapeutic purposes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QL1706-106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.